Jesse Goodman is a professor of medicine at Georgetown University and the director of the Center on Medical Product Access, Safety, and Stewardship. He is an attending physician in infectious diseases at Georgetown University, the Washington, D.C. Veteran’s Administration, and Walter Reed Medical Centers. He coordinates a multi-institution National Capital Region Coalition on Antimicrobial Resistance and the COVID Vaccine Analysis Team, a multi-expert group providing analysis of emerging information on COVID-19 vaccines.
He previously served as chief scientist and deputy commissioner for science and public health of the U.S. Food and Drug Administration (FDA). Before his role as chief scientist, he directed the FDA’s Center for Biologics Evaluation and Research and before that, served as senior advisor to the FDA commissioner, where he co-chaired the first U.S. Task Force to Combat Antimicrobial Resistance. Previously, he was a professor of medicine and chief of infectious diseases at the University of Minnesota, where his laboratory isolated A. phagocytophilum, the causative agent of the tick-borne disease human granulocytic anaplasmosis. He has served on various CDC, NIH, DOD, CEPI, and WHO advisory committees and is on the CDC’s Board of Scientific Counselors for Infectious Diseases. He served as president of the U.S. Pharmacopeia from 2015 to 2020 and remains a trustee to this day. He serves on the board of GSK, chairing its science committee, and on the Board of Intellia Therapeutics, which is developing gene editing to treat human diseases. He has been elected to the National Academy of Medicine of the National Academy of Sciences.